131 related articles for article (PubMed ID: 37451410)
1. In vitro identification of decreased function phenotype ABCG2 variants.
Suominen L; Sjöstedt N; Vellonen KS; Gynther M; Auriola S; Kidron H
Eur J Pharm Sci; 2023 Sep; 188():106527. PubMed ID: 37451410
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Sjöstedt N; van den Heuvel JJMW; Koenderink JB; Kidron H
Pharm Res; 2017 Aug; 34(8):1626-1636. PubMed ID: 28281205
[TBL] [Abstract][Full Text] [Related]
3. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
[TBL] [Abstract][Full Text] [Related]
5. Functional Characterization of Clinically-Relevant Rare Variants in
Toyoda Y; Mančíková A; Krylov V; Morimoto K; Pavelcová K; Bohatá J; Pavelka K; Pavlíková M; Suzuki H; Matsuo H; Takada T; Stiburkova B
Cells; 2019 Apr; 8(4):. PubMed ID: 31003562
[TBL] [Abstract][Full Text] [Related]
6. Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
[TBL] [Abstract][Full Text] [Related]
7. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Morisaki K; Robey RW; Ozvegy-Laczka C; Honjo Y; Polgar O; Steadman K; Sarkadi B; Bates SE
Cancer Chemother Pharmacol; 2005 Aug; 56(2):161-72. PubMed ID: 15838659
[TBL] [Abstract][Full Text] [Related]
10. ABCG2/BCRP dysfunction as a major cause of gout.
Matsuo H; Takada T; Ichida K; Nakamura T; Nakayama A; Suzuki H; Hosoya T; Shinomiya N
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1117-28. PubMed ID: 22132966
[TBL] [Abstract][Full Text] [Related]
11. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
Toyoda Y; Pavelcová K; Bohatá J; Ješina P; Kubota Y; Suzuki H; Takada T; Stiburkova B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669292
[TBL] [Abstract][Full Text] [Related]
12. The frequency of rs2231142 in
Alrajeh K; Roman YM
Pharmacogenomics; 2023 Jan; 24(1):15-26. PubMed ID: 36651271
[TBL] [Abstract][Full Text] [Related]
13. Functional non-synonymous variants of ABCG2 and gout risk.
Stiburkova B; Pavelcova K; Zavada J; Petru L; Simek P; Cepek P; Pavlikova M; Matsuo H; Merriman TR; Pavelka K
Rheumatology (Oxford); 2017 Nov; 56(11):1982-1992. PubMed ID: 28968913
[TBL] [Abstract][Full Text] [Related]
14. Interindividual Regulation of the Breast Cancer Resistance Protein/
Bircsak KM; Moscovitz JE; Wen X; Archer F; Yuen PYS; Mohammed M; Memon N; Weinberger BI; Saba LM; Vetrano AM; Aleksunes LM
Drug Metab Dispos; 2018 May; 46(5):619-627. PubMed ID: 29386232
[TBL] [Abstract][Full Text] [Related]
15. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of SNPs variants of BCRP/ABCG2.
Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y
Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238
[TBL] [Abstract][Full Text] [Related]
17. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
[TBL] [Abstract][Full Text] [Related]
18. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
[TBL] [Abstract][Full Text] [Related]
19. Identification of ABCG2 dysfunction as a major factor contributing to gout.
Matsuo H; Takada T; Ichida K; Nakamura T; Nakayama A; Takada Y; Okada C; Sakurai Y; Hosoya T; Kanai Y; Suzuki H; Shinomiya N
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1098-104. PubMed ID: 22132963
[TBL] [Abstract][Full Text] [Related]
20. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
